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Abstract
Background: Discriminating acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) from cardiogenic
pulmonary edema (CPE) is often challenging. This systematic review examines studies using biomarkers or images
to distinguish ALI/ARDS from CPE.
Methods: Three investigators independently identified studies designed to distinguish ALI/ARDS from CPE in
adults. Studies were identified from PubMed, and the Cochrane Central Register of Controlled Trials database
until July 3, 2017.
Results: Of 475 titles and abstracts screened, 38 full texts were selected for review, and we finally included 24
studies in this systematic review: 21 prospective observational studies, two retrospective observational studies,
and one retrospective combined with prospective study. These studies compared various biomarkers to differentiate
subjects with ALI/ARDS and in those with CPE, and 13 calculated the area under the receiver operator characteristic
curve (AUC). The most commonly studied biomarker (four studies) was brain natriuretic peptide (BNP) and the
discriminatory ability ranged from AUC 0.67–0.87 but the timing of measurement varied. Other potential biomarkers
or tools have been reported, but only as single studies.
Conclusions: There were no identified biomarkers or tools with high-quality evidence for differentiating ALI/ARDS
from CPE. Combining clinical criteria with validated biomarkers may improve the predictive accuracy.
Keywords: Heart failure, Acute respiratory failure, Pulmonary edema, Biomarkers

Background
Differentiating between cardiogenic pulmonary edema
(CPE) and acute lung injury (ALI) or acute respiratory
distress syndrome (ARDS) is challenging in the early
stages of illness [1]. The most widely accepted definition of ALI/ARDS had been based on the AmericanEuropean Consensus Conference (AECC) definition, of
acute onset respiratory failure with bilateral infiltrates
on chest radiograph, and pulmonary capillary wedge
pressure (PCWP) <18 mmHg, or absence of elevated
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left atrial pressure [2]. However, pulmonary artery
catheterization is rarely used in clinical practice because clinical estimation of PCWP is invasive, costly,
and does not aid in the diagnosis of ALI/ARDS [3–7].
There were potential inconsistencies in this definition,
including a lack of explicit criteria for defining acute respiratory failure, the sensitivity of the PaO2/FiO2 (P/F)
ratio to ventilator settings, poor reliability of the chest
radiograph criteria, and difficulties distinguishing ARDS
from CPE including that these diagnoses can coexist
[8, 9]. Based on these limitations, the Berlin definition
for ARDS was published in 2012 and is reported to
have better predictive validity for mortality, than this
earlier definition [8]. Pulmonary capillary wedge pressure measurement was removed from this definition.
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Patients were presumed to have ARDS if they had respiratory failure not fully explained by cardiac failure
or fluid overload as judged by the treating physician
using all available data.
In current practice and most clinical studies, ALI/
ARDS is usually differentiated from CPE by the clinical
circumstances and by physical findings, but this distinction is often made only by post hoc review after patient’
discharge or death, and is often based on the response
to therapy [10, 11]. The ARDS Clinical Trial Network
reported that fluid management to decrease cardiogenic fluid retention and the effects of lung permeability and edema, will shorten the duration of mechanical
ventilation and intensive care without increasing nonpulmonary organ failure [12]. The differentiation between ALI/ARDS and CPE is important in order to
avoid delaying treatment of fluid retention and avoiding
unnecessary testing [13]. Several biomarkers to distinguish ALI/ARDS from CPE have been reported. The
aim of this systematic review was to review published
studies of potential biomarkers to distinguish ALI/
ARDS from CPE.

Methods
This systematic review was conducted using the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) and the Meta-analysis of
Observational Studies in Epidemiology (MOOSE)
guidelines [14].
Search criteria

We included prospective or retrospective cohort studies
written in English, which evaluated biomarkers or images for differentiating ALI/ARDS from CPE in adults.
Studies that did not refer ALI/ARDS based on the
AECC or the Berlin definition were excluded from this
systematic review [2, 8]. We identified studies from the
PubMed database using the search terms: “acute lung
injury [All Fields] OR acute respiratory distress syndrome [All Fields] OR pneumonia [All Fields] AND
cardiogenic pulmonary edema [All Fields] OR hydrostatic pulmonary edema [All Fields] OR ARDS diagnostics [All Fields] OR decompensated heart failure [All
Fields]”, and from the Cochrane Central Register of
Controlled Trials database using the search terms:
“acute lung injury AND cardiogenic pulmonary edema”,
“acute respiratory distress syndrome AND cardiogenic
pulmonary edema”, and “pneumonia AND cardiogenic
pulmonary edema” (accessed on July 3, 2017). All included studies focused on distinguishing “pure” ALI/
ARDS from “pure” CPE. Mixed cases were excluded
from analysis. Studies published only in abstract form
were excluded. Full texts of articles were further evaluated by three investigators (KK, TA, and YK).
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Data extraction

We extracted the following information from included
studies: study design, sample size, diagnostic methods of
ALI/ARDS or CPE, assessed markers, mean value of the
markers in ALI/ARDS or CPE, the area under the receiver
operator characteristic curve (AUC), and specificity and
sensitivity for ALI/ARDS or CPE at a cutoff.
Assessing risk of bias

The risk of bias in the included studies was assessed
according to the recommendations outlined in the
Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. and MOOSE guidelines for the following items: selection, performance, detection, attrition,
and publication bias [14]. Each study included in this review was assessed for quality as good, moderate, or poor
based on biases using the modified Hayden’s criteria
[15], which included source population, sample size,
inclusion criteria, how to determine the final diagnosis
of ALI/ARDS or CPE, and analysis providing sufficient
presentation of data. Three investigators independently
determined the quality based on these points. Disagreements among the investigators were resolved by review
of the assessments to reach consensus.

Results
Database search and characteristics of included studies

We identified 475 studies through PubMed and CENTRAL
databases, and then excluded 437 studies as the abstract
did not meet the inclusion criteria. We excluded 14 of
the remaining 38 records after retrieving and inspecting
the full text (Fig. 1).
We finally included 24 studies in this systematic review: ten studies using systemic biomarkers which were
measured in plasma [the quality of these studies by the
modified Hayden’s criteria was, good (n = 6) [10, 16–20],
moderate (n = 1) [21], and poor (n = 3) [22–24]], and 11
studies using “lung-specific” biomarkers measured in
bronchoalveolar lavage (BAL) or pulmonary edema
fluid [quality was good (n = 2) [25, 26] and poor (n = 9)
[27–35]], three studies of chest ultrasonography or
computed tomography (CT) [good (n = 1) [36] and
moderate (n = 2) [37, 38]]. Most were reported as prospective cohort studies but two studies were retrospective and one study combined a retrospective cohort with
a prospective cohort. These studies were published
from the USA (n = 10), Japan (n = 5), Germany (n = 2),
Australia (n = 2), China (n = 2), Italy (n = 1), Belgium
(n = 1), The Netherlands (n = 1), Taiwan (n = 1), and
Switzerland (n = 1).
Sixteen studies diagnosed either ALI/ARDS or CPE
using clinical information [10, 16–18, 21, 22, 24–27, 29,
30, 34, 36–38], and in eight studies the final diagnosis
was confirmed by at least two independent reviewers
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Records identified through database
searching from PubMed and CENTRAL.
(n = 475)

Full-text articles assessed for eligibility
(n = 38)
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Excluded (n = 437)
Not written in English (n = 85)
Review without data (n = 96)
Case report (n = 29)
Letter or statement (n = 22)
Mismatched sample (n = 84)
Mismatched intervention / outcomes (n = 84)
Not a clinical trial (n = 18)
Duplicate or overlapping data (n = 17)
Mixed cases combined with ALI/ARDS group (n = 2)

Excluded (n = 14)
No diagnostic criteria listed for ALI/ARDS or CPE (n = 8)
No description of mean value of marker or score (n = 6)
Studies with eligible data
(n = 24)
Systemic marker (n = 10)
Local marker (n = 11)
Image (n = 3)
Fig. 1 Flow diagram of the study selection

[10, 16–18, 21, 26, 36, 37]. Six studies [19, 20, 23, 32, 33,
35] used the results of PCWP by pulmonary artery
catheterization and two studies used the edema fluid
protein/plasma protein ratio to differentiate ALI/ARDS
from CPE [28, 31].
Systemic biomarkers

Nine of ten studies that evaluated systemic markers to
distinguish ALI/ARDS from CPE assessed predictive
power using AUC. Brain natriuretic peptide (BNP) was
the most commonly assessed biomarker (Table 1). The
discriminatory ability to differentiate CPE from ARDS
varied among four studies with AUC, 0.67–0.83. The
levels of plasma CRP in patients with ALI/ARDS were
significantly higher than those with CPE [18, 33]. In
these studies, subjects thought to have both ALI/ARDS
and CPE were explicitly excluded from the analysis.
Komiya and colleagues showed that when C-reactive
protein was used to differentiate CPE from ALI/ARDS,
the AUC was as good as BNP, and the AUC when the
combination of BNP and CRP was used to differentiate
CPE from ALI/ARDS was significantly higher than either
BNP or CRP alone.
The plasma soluble suppression of tumorigenicity-2
[20], heparin-binding protein [39], and copeptin [16]
were evaluated in single studies that showed high predictive value for differentiating ALI/ARDS from CPE.

Arif and colleagues reported that pulmonary leak
index was significantly higher in ARDS than in CPE
patients and the AUC for ARDS was 0.98 for transferrin, 0.95 for total protein, and 0.80 for albumin levels
in plasma [22]. Other studies compared mean value of
mucin-associated antigen in serum, or arteriovenous
differences in lactate between ALI/ARDS and CPE but
the sample size for each of these studies was small,
and the methods used as the standard for diagnosis
were unclear.
Lung biomarkers

Only one of the 11 studies that evaluated “lung-specific”
biomarkers used AUC to evaluate their ability to distinguish ALI/ARDS from CPE (Table 2). Ware and colleagues showed that the fluid-to-plasma protein ratio
had a high AUC and good sensitivity and specificity for
differentiating ALI from CPE, and that a fluid to plasma
ratio >0.65 was associated with higher mortality and
more days requiring mechanical ventilation [25]. Schutte
and colleagues reported that the protein concentration
in BALF from ALI/ARDS subjects was higher than in
CPE [33]. In two studies, surfactant apoprotein (SP)-A
was significantly greater in BALF from subjects with
CPE compared to those with ALI/ARDS [32, 35].
Laminin gamma-2 fragments are parts of laminin-5,
which is a cellular adhesion molecule expressed solely

Design

51 vs 23

Levitt, 2008** Prospective

Prospective

Retrospective + 131 vs 73
Prospective

Karmpaliotis,
2007***

Rana,
2006***

13 vs 5

43 vs 9

Prospective

Prospective

Prospective

Lin Q,
2012***

Arif, 2002*

Shih, 1997*

Backer, 1997* Prospective

Median
3 h after
diagnosis

Not stated
344 (IQR122–745)

325 (IQR82–767)

369 (IQR87–709)

n.d.

119 (IQR62–165)

202 (IQR95–439)

534 (IQR325.0–724.9)

AVLAC

Not stated

Not stated
0.20 ± 0.230 SD

53.8 ± 6.6 SEM

32.3 (range23.0–54.4)

Pulmonary
leak index
MAA in
serum

25 (range17–34)

Alb in
plasma

1.0 (range 0.5–1.5)
49 (range 41–59)

Within 72 h
of ICU adm.

At enrollment 52.53 (IQR29.81–91.43)

TP in
plasma

Transferrin
in plasma

Copeptin

Plasma HBP At enrollment 17.15 (IQR11.95–24.07)

BNP

BNP

BNP

Within 48 h
of ICU adm.

at ER

CRP
BNP + CRP

Within 2 h
after arriving

The day of
enrollment

BNP

ST-2

0.139 ± 0.176 SD

9.0 ± 3.1 SEM

10.1 (range 4.4–16.2)

30 (range 25–43)

63 (range 51–69)

2.1 (range 1.5–2.7)

25.14 (IQR21.04–34.26)

9.50 (IQR7.98–12.18)

759 (IQR378–1320)

1260 (IQR541–2020)

600 (IQR352–1300)

n.d.

8 (IQR2–42)

691 (IQR416–1194)

43 (IQR26.4–78.6)

NS

<0.001

mEq/L

ng/mL

<0.001

<0.05

X10^-3/m <0.001

g/L

g/L

<0.001

<0.001

pmol/L

<0.001

0.0001

0.04

n.d.

<0.001

<0.001

<0.001

g/L

AUC

n.d.

n.d.

0.52–0.81

n.d.

n.d.

1

0.8

0.95

0.98

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

0.823 ±0.038

0.851 ±0.040

0.71

0.79

0.67

0.931 0.884–0.978

0.887 0.826–0.948

n.d.

n.d.

16.3

24

59

1.5

40.11

11.55

250

200

100

n.d.

50

500

n.d.

n.d.

ARDS

ARDS

ARDS

ARDS

ALI/
ARDS

ALI/
ARDS

ALI/
ARDS

ALI/
ARDS

ALI/
ARDS

n.d.

ALI/
ARDS

CPE

ALI/
ARDS

Cutoff For

n.d. (p <0.0001) 142

SD or 95% CI

0.831 0.759–0.904

<0.0001 0.98

p value

ng/mL

pg/mL

pg/mL

pg/mL

n.d.

mg/L

pg/mL

ng/mL

Timing of
Mean value ± SD/SEM
Mean value ± SD/SEM
Unit
measurement or median (IQR or range) or median (IQR or range)
in ALI/ARDS
in CPE

n.d.

n.d.

100

100

75

87

88.2

78.2

90

91

95.2

n.d.

69.8

83.1

91

n.d.

n.d.

100

45

100

100

60.9

75

40

40

27.3

n.d.

59.2

69

94

Specificity Sensitivity
(%)
(%)

Alb albumin, ALI acute lung injury, ARDS acute respiratory distress syndrome, AUC area under the curve, AVLAC arteriovenous differences in lactate, BNP brain natriuretic peptide, CPE cardiogenic pulmonary
edema, CRP C-reactive protein, ER emergency department, HBP heparin-binding protein, MAA mucin-associated antigen, n.d. not described, SP-A surfactant Protein-A, SP-B surfactant protein-B, SEM standard
error of the mean, SD standard deviation, ST-2 suppression of tumorigencity-2, TP total protein
***good, **moderate, or *poor quality assessed based on the modified Hayden’s criteria

11 vs 12

87 vs 34

Prospective

Lin Q,
2013***

78 vs 28

33 vs 21

Prospective

Komiya,
2011***

Other circulating markers

53 vs 71

Retrospective

826 vs 87

No. of ALI/
marker
ARDS vs CPE

Bajwa,
2013***

Markers of cardiomyocyte stress

Study

Table 1 Systemic markers differentiating ALI/ARDS from CPE
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Design

Prospective 23 vs 9

Prospective 15 vs 5

Kropski, 2009*

Chandel, 2009*

Prospective 15 vs 13

Gunther, 1996*

Prospective 12 vs 6

Prospective 27 vs 8

Schutte, 1996*

Miller, 1996*

22 (IQR9–44)

1950 (IQR1780–4024)

217 ± 79

Not stated

0.89 ± 0.36 SD

PVPI

EVWI

Not stated
3.2 ± 1.4 SD

18.5 ± 6.8 SD

Within 30 min 0.90 ± 0.09 SEM in
after intubation w/o sepsis, 0.84 ± 0.16
SEM in w sepsis,

235 ± 33 SEM

Protein in
PEF/plasma

16.1 ± 5.8 SEM

Serum CRP*

Within 72 h
671 ± 256 SEM
after intubation

PMN in BAL

Protein in BAL

Protein ratio of fluid Within 1–4 h
Prim. 0.32 ± 0.42 SD,
by s-Cath to plasma after intubation Sec. 0.81 ± 0.33 SD

Fluid-to-plasma
protein ratio

867 ± 131 SEM

SP-B in BAL

311 ± 47 SEM

Within 72 h
849 ± 96 SEM
after intubation

Not stated

Within 15 min 1451 ± 6 727
after intubation

Within 48 h
1.2-fold ±0.12 SD
after intubation

Within 24 h
of diagnosis

147 ± 83 SD

6034 ± 6245 SD

2.0 ± 0.8 SD

14.4 ± 4.0 SD

0.48 ± 0.12 SEM

93 ± 25 SEM

0.4 ± 0.11 × 10^6

291 ± 81 SEM

0.20 ± 0.19 SD

0.53 ± 0.21 SD

628 ± 42 SEM

1013 ± 111 SEM

1324 ± 197 SEM

335 ± 123

335 ± 123

2.4-fold ±0.48 SD

55 (IQR18–123)

4835 (IQR2006–6350)

35 ± 14 SD

1237 ± 807 SD

p value

<0.01

n.d.

mL/kg

Ratio

mg/L

/mL

0.84

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

AUC

<0.01

<0.01

<0.05

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

0.79-0.88

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

95% CI

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

0.65

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

Cutoff

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

0.95

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

81

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

Specificity Sensitivity
(%)
(%)

ALI/ 81
ARDS

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

n.d.

For

0.886 0.836-0.953 2.6–2.85 ALI/ 0.9
ARDS

n.d.

n.d.

n.d.

n.d.

n.d.

0.002 in
n.d.
Sec. vs CPE

<0.001

ug/mL n.d.

n.d.

n.d.

ng/mL n.d.

ng/mL n.d.

ug/mL <0.001

ug/mL <0.05

ug/mL <0.0001

fold

ng/mL 0.053

ng/mL 0.044

ng/mL <0.0001

ng/mL <0.02

Unit
Mean value ± SD/SEM
Mean value ± SD/SEM
or median (IQR or range) or median (IQR or range)
in CPE
in ALI/ARDS

SP-A in BAL

SP-A in sputum

HTI56 in plasma

HTI56 in PEF

KGF in BAL

CCP 16 in serum

CCP 16 in PEF

Laminin gannma2
in plasma

Not stated

Timing of
measurement

ALI acute lung injury, ARDS acute respiratory distress syndrome, AUC area under the curve, BAL bronchoalveolar lavage, CPE cardiogenic pulmonary edema, CCP Clara cell protein, CRP C-reactive protein,
ELF epithelial lining fluid, EVWI extravascular lung water index, HTI56 human type I cell-specific apical membrane protein, KGF keratinocyte growth factor, n.d. not described, n.s. not significant, PEF pulmonary
edema fluid, PMN polymorphonuclear neutrophils, PVPI pulmonary vascular permeability index, s-Cath suction catheter, SD standard deviation, SEM standard error of the mean, SP-A surfactant Protein-A,
SP-B surfactant protein-B
***Good, or *poor quality assessed based on biases using the modified Hayden’s criteria

Kushimoto,
2012***

Prospective 207 vs 26

Prospective 18 vs 9

Colucci, 2009*

Others

Prospective 209 vs 147

Ware, 2010***

Protein ratio of fluid to plasma

Prospective 5 vs 11

Shimura,1996*

Newman, 2000* Prospective 15 vs 12

Prospective 21 vs 11

Katayama,
2010*

Laminin gannma2
in ELF

No. of ALI/
Marker
ARDS vs CPE

Markers of airway epithelium injury

Study

Table 2 Localized markers for differentiating ALI/ARDS from CPE

Komiya et al. Critical Care (2017) 21:228
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by epithelium, and promotes epithelial cell migration
and repair of injured epithelium [40]. The concentration of these fragments in epithelial lining fluid from
subjects with ALI/ARDS was significantly higher than
those with CPE, and the concentration of laminin
gamma-2 fragments at 5 days after onset also was associated with mortality [27].
Imaging studies

Copetti and colleagues evaluated the ability of chest
ultrasound to detect characteristic signs of ALI/ARDS vs
CPE [38] (Table 3). During normal breathing, sonography can detect the lung moving or “sliding” along the
pleura, but this sliding is impaired when there are inflammatory adhesions. While subjectively, normal lung
sliding is seen in subjects with CPE, it is absent or decreased in subjects with ALI/ARDS. “B lines” on chest
sonography (distinct from Kerly B lines on plain radiography, and previously called comet-tail artifacts), are
generated from the thickened interlobular septa (e.g.,
seen in interstitial edema) at the lung wall interface [41].
Sekiguchi and colleagues reported that a higher “B-line
ratio” (proportion of chest zones with positive B lines
relative to all zones examined) was specific for the diagnosis of CPE, and that findings of a left-sided pleural
effusion >20 mm, moderate or severe left ventricle dysfunction, and minimal diameter of inferior vena cava
>23 mm were helpful to distinguish CPE from ALI/
ARDS using a derived, simplified prediction score as
shown in Table 3 [36]. Some features on chest CT were
reported to better differentiate ARDS from CPE. Small
ill-defined opacities, defined as patchy areas of groundglass attenuation or airspace consolidation, and leftdominant pleural effusion had high specificity for ALI/
ARDS in a single-center retrospective study [37].

Discussion
We systematically reviewed serum and pulmonary biomarkers, and imaging used to differentiate ALI/ARDS
from CPE. BNP, released from ventricular cardiomyocytes in response to both ventricle volume expansion
and pressure overload, was the most commonly evaluated biomarker; but the predictive ability was variable.
While two studies measured BNP levels early in the
clinical presentation, and these showed a good discriminatory ability [18, 19], other studies allowed BNP to be
tested up to 3 hours (IQR 0.5–14) [10] or 48 hours
after presentation and these were less able to distinguish ARDS/ALI from CPE [21]. BNP is known to decrease after treatment for heart failure [42] and this
could explain the higher discriminatory ability before
starting treatment. Replicate and prospective studies
with consistent timing of measurements are required in
order to improve the quality of evidence.
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As well, the subjects in the study by Levitt [21] were
younger than in the other studies [10, 18, 19] and in the
younger subjects BNP was a less sensitive biomarker. Because elderly patients may respond less well to diuretics,
ACE inhibitors, and inotropic agents compared to younger patients [43], the younger patients may also respond
to treatment more rapidly. Renal failure often accompanies severe sepsis and ARDS and this can increase
BNP despite normal cardiac function [44]. Due to these
different patient characteristics in each study, we did not
collect these raw data to combine for a meta-analysis.
CRP is widely used as a marker of systemic inflammation, and in one study by the authors of this review;
AUC when CRP was used to differentiate ALI/ARDS
from CPE was as good as when BNP was used [18].
While BNP levels can increase in some conditions such
as renal failure or sepsis despite normal cardiac function
[44], CRP is not directly influenced by cardiac function.
CRP combined with BNP may have greater discriminatory ability than either BNP or CRP alone [18].
Plasma soluble suppression of tumorigenicity-2, an IL1 receptor family member which is a mediator of inflammation and immunity, showed excellent discrimination
[20]. Heparin-binding protein is an antimicrobial protein
stored in neutrophil granules, and it induces cytoskeletal
rearrangement of endothelial cells, which leads to breakdown of cell barriers and an increase in macromolecular
efflux [39]. Copeptin, the C-terminal portion of the arginine vasopressin precursor, is secreted together with
arginine vasopressin precursor from the neurohypophysis. This secretion is thought to reflect the inflammatory
cytokine response and the presence of hemodynamic
and osmoregulatory disturbances [45, 46]. These biomarkers appeared to be robust in discriminating ALI/
ARDS from CPE in single studies; so validation in replicate studies will be necessary.
Sample size in each study for lung-specific biomarkers
was small compared with studies of serum biomarkers,
and airway sampling by BAL may be difficult in the
emergency department setting. When pulmonary edema
is present, pulmonary edema fluid can be obtained by
inserting a suction catheter into an endotracheal tube
until frothy fluid is obtained by suctioning [25]. The pulmonary edema fluid-to-plasma protein ratio has been
studied for decades as a tool to differentiate pulmonary
permeability edema from hydrostatic edema [47].
Combining cardiac and thoracic ultrasonography
could help to determine the cause of acute pulmonary
edema [36]. However, these techniques are operator-skill
dependent. Chest CT may be better at discriminating
ALI/ARDS from CPE than chest radiography; although
CT is rarely performed for acute respiratory failure in
the emergency department setting. Milne and colleagues
performed an independent two-observer study of chest

Prospective

Retrospective

Prospective

Sekiguchi, 2015***

Komiya, 2013**

Copetti, 2008**

18 vs 40

20 vs 41

42 vs 59

No. of ALI/
ARDS vs CPE

Lung pulse

Pleural effusion

Consolidations

Spared areas

Reduction or absence of lung sliding

Pleural line abnormalities

Alveolar-interstitial syndrome

100
50

CPE

33.3

CPE
ALI/ARDS

5

ALI/ARDS

100
0

ALI/ARDS

0

CPE

CPE

100

ALI/ARDS

100
0

ALI/ARDS
CPE

45
0

ALI/ARDS
CPE

0
0

ALI/ARDS

95.1

87.8

90

90

95

98 (95% CI 87–100)

42 (95% CI 32–52)

Specificity (%)

CPE

ARDS

Left-dominant pleural effusion
Not stated

Small ill-defined opacities

Chest sonography

CPE
ARDS

Central airspace consolidation

CPE

CPE

Miscellaneous
causes

For

CPE

>=6

3

Cutoff

Central-predominant GGA

Within 2 hours
of arrival at ED

0.70–0.87

0.75–0.88

95% CI

Upper-lobe-predominant GGA

Chest CT

0.79

Score; left pleural effusion >20 mm
(+4), Moderate or severe LV
dysfunction (+3), and IVC minimal
diameter < =23 mm (-2).

AUC

0.82

Within 6 h
of diagnosis

Timing of
measurement

Number of chest zones
with positive B-lines

Combined cardiac and
thoracic ultrasonography

Marker

0

50

95

66.6

0

83.3

0

100

0

100

25

100

100

100

25

35

56.1

58.5

48.8

39 (95% CI 26–52)

100 (95% CI 89–100)

Sensitivity (%)

ALI acute lung injury, ARDS acute respiratory distress syndrome, AUC area under the curve, B-lines vertical narrow based lines arising from the pleural line to the edge of the ultrasound screen, CT computed
tomography, CPE cardiogenic pulmonary edema, GGA ground-glass attenuation, ED emergency department, IVC inferior vena cava, LV left ventricular
***Good, or **moderate quality assessed based on biases using the modified Hayden’s criteria
Miscellaneous including unilateral pneumonia, atelectasis, COPD, pulmonary embolism or pneumothorax

Design

Study

Table 3 Imaging to differentiate ALI/ARDS from CPE
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radiographs from 61 subjects with cardiac disease, and
28 with capillary permeability edema, not described as
ALI or ARDS [48]. The overall accuracy for distinguishing capillary permeability edema from cardiac edema
was 91%. Another study reported that 87% of subjects
with hydrostatic edema but only 60% of those with
increased permeability edema were correctly identified
in critical ill patients [49]. It is controversial if chest
radiography can be recommended to differentiate the
type of pulmonary edema.
A limitation of studies focusing on biomarkers or images for discriminating ALI/ARDS from CPE is that
these can coexist [8]. Some degree of hydrostatic edema
is present in many cases of ALI/ARDS, in fact the
pulmonary capillary wedge pressure is reported to be
elevated in 30% of ARDS patients [12]. Schmickl and
colleagues developed a decision support algorithm to
distinguish CPE from ARDS based on clinical data [11].
However, while all studies included in this systematic
review specifically excluded mixed cases of ALI/ARDS
with CPE, these authors included these cases in the
ALI/ARDS group. Protein biomarkers such as BNP
showed no statistically significant difference when comparing “pure” CPE with serum from subjects with ALI/
ARDS both with and without CPE. BNP levels were elevated for both ALI/ARDS with and without CPE and
pure CPE (708 pg/mL vs 749 pg/mL; p = 0.18). Strict
fluid management that addresses cardiogenic pulmonary edema and pulmonary permeability edema increases
ventilator-free days [12]. This suggests that biomarkers
like BNP could be useful for differentiating CPE from
ALI/ARDS and for initiating fluid restriction and diuretics early to decrease the risk of CPE.
We identified that some biomarkers, e.g., soluble suppression of tumorigencity-2, BNP plus CRP, heparinbinding protein, and plasma transferrin had high AUCs
for differentiating ALI/ARDS from CPE, but these
were each only assessed in a single study. All studies
compared the biomarker measurement to the clinical
diagnosis, but no study compared accuracy of the clinical diagnosis alone to that of clinical diagnosis plus
biomarkers. Since ALI/ARDS and CPE can certainly
co-exist, biomarkers need to be considered to evaluate
the relative role of CPE in contributing to the morbidity
of ALI/ARDS.
Because there are no accepted criteria for differentiating CPE from ALI/ARDS at the time of clinical presentation, for these studies, the decision to classify as
ALI/ARDS versus CPE was made by clinical expert(s)
reviewing clinical information and response to therapy
including diuretics. The fundamental questions are: are
biomarkers measured at clinical presentation more reliable (and accessible) than post hoc experts’ opinion in
differentiating these conditions and can biomarkers
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identify patients who should have therapy for both conditions (coexisting). Neither question was answered by
this systematic review, largely because there is no true
gold standard for distinguishing ARDS/ALI from CPE.
Given this limitation we understood that the purpose
of this review was to identify potential biomarkers that
would most closely correlate with expert clinical judgement, which was often post hoc – after the diagnosis
became clear. If these biomarkers could be then used
for earlier detection and intervention, as suggested by
the studies showing that BNP appeared to be most useful when measured at the time of presentation in the
emergency department and before initiating therapy,
this may allow guidance of appropriate intervention before such time that the clinical differentiation is clear.

Conclusions
We found that there were no identified biomarkers or
tools with high-quality evidence for differentiating ALI/
ARDS from CPE. Because there is no objective “gold
standard” for diagnosing ALI/ARDS or CPE, a clear
distinction between ALI/ARDS and CPE may not have
been possible in any of these reported studies. The
eventual diagnosis was determined by post hoc expert
review, blinded to target marker. These limitations pose
an obstacle to developing a reliable method to differentiate these disorders. However, differentiating the cause
of pulmonary edema is important because the therapy
of ALI/ARDS and CPE are fundamentally different.
Although fluid restriction might be used to treat both
CPE and ARDS/ALI, early recognition of ALI/ARDS
allows an emphasis on lung-protective ventilation and
in the treatment of the underlying cause of the ARDS
whilst recognition of CPE may lead to the appropriate
use of diuretics, inotropic therapy, and afterload reduction. Combining clinical criteria with validated biomarkers may improve the predictive accuracy and
improve the outcomes of ALI/ARDS even it co-exists
with CPE.
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